https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial – ANZGOG 0903 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45582 p = 0.002), cognitive functioning (45 vs 19%: p = 0.021), fatigue (47 vs 19%: p = 0.015) and global health status (42 vs 9%: p = 0.003). Conclusion: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.]]> Wed 02 Nov 2022 10:37:04 AEDT ]]> Randomised controlled trial to change the hospital management of unstable angina https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1329 Sat 24 Mar 2018 08:32:33 AEDT ]]> Randomised controlled trial of health assessments for older Australian veterans and war widows https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1882 Sat 24 Mar 2018 08:31:19 AEDT ]]> Paragon (ANZGOG-0903): phase 2 study of Anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34256 Mon 25 Feb 2019 11:25:06 AEDT ]]> PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45708 Fri 04 Nov 2022 10:18:27 AEDT ]]>